科华生物(002022) - 2021 Q1 - 季度财报

Financial Performance - Revenue for Q1 2021 reached ¥1,453,210,918.22, representing a 170.82% increase compared to ¥536,588,796.53 in the same period last year[8] - Net profit attributable to shareholders was ¥342,225,938.64, a significant increase of 584.50% from ¥49,996,448.89 year-on-year[8] - Net profit excluding non-recurring items was ¥340,651,901.14, up 636.54% from ¥46,250,398.68 in the previous year[8] - Basic earnings per share rose to ¥0.6717, a 588.92% increase from ¥0.0975 in the same period last year[8] - Diluted earnings per share increased to ¥0.6410, up 558.79% from ¥0.0973 year-on-year[8] - The total comprehensive income for the period was ¥521,524,387.68, compared to ¥81,775,983.57 in the previous year, showcasing strong financial performance[48] - The company reported a net profit of CNY 2,279,683,562.64 in retained earnings, up from CNY 1,937,457,624.00, indicating an increase of approximately 17.7%[40] - The net profit for the first quarter of 2021 was ¥19,601,954.15, a significant recovery from a net loss of ¥21,347,767.09 in the same period last year[50] - Operating profit reached ¥22,274,246.88, compared to an operating loss of ¥26,438,851.96 in the previous year[50] Cash Flow and Assets - Operating cash flow for the period was ¥352,209,941.61, reflecting a 535.18% increase compared to ¥55,450,002.38 in the same quarter last year[8] - Cash flow from operating activities amounted to ¥352,209,941.61, a substantial increase from ¥55,450,002.38 in the prior year[54] - The company reported cash and cash equivalents of ¥2,304,549,028.29 at the end of the quarter, up from ¥473,115,095.63 at the end of the previous year[55] - The total cash and cash equivalents at the end of the period amounted to 553,782,113.92 CNY, down from 650,012,029.04 CNY at the beginning of the period[58] - The company reported a total asset value of 5,977,153,474.43 CNY, with total liabilities amounting to 2,078,117,027.37 CNY[62] - Current assets totaled CNY 4,421,142,847.99, up from CNY 4,008,542,632.93, indicating an increase of about 10.3%[37] - Total assets at the end of the reporting period were ¥6,429,473,562.87, a 7.57% increase from ¥5,977,153,474.43 at the end of the previous year[8] Expenses and Liabilities - Operating costs rose by 104.34% year-on-year, mainly due to a significant increase in product sales volume[16] - Financial expenses increased by 56.24% year-on-year, primarily due to the amortization of interest adjustments on convertible bonds issued in 2020[18] - Credit impairment losses surged by 958.98% year-on-year, attributed to rapid growth in accounts receivable and increased bad debt provisions[19] - Sales expenses rose by 71.09% year-on-year, resulting from variable sales costs associated with revenue growth[17] - Total liabilities decreased to CNY 2,005,352,877.20 from CNY 2,078,117,027.37, a reduction of about 3.5%[39] - The total liabilities decreased to ¥970,327,125.83 from ¥1,050,446,901.44 year-over-year[46] Shareholder Information - The weighted average return on equity improved to 10.33%, an increase of 8.23 percentage points from 2.10% in the previous year[8] - Net assets attributable to shareholders increased to ¥3,474,571,447.49, up 10.62% from ¥3,140,958,791.90 at the end of the last year[8] - The total number of ordinary shareholders at the end of the reporting period was 66,399[11] - Total equity increased to ¥1,997,316,172.39 from ¥1,974,994,618.13, indicating a growth in shareholder value[46] Research and Development - Research and development expenses grew by 58.99% year-on-year, reflecting continued investment in new product development[17] - Research and development expenses rose to ¥27,385,839.26, up from ¥17,225,283.54, reflecting the company's commitment to innovation[46] Market and Future Outlook - Total revenue increased by 170.82% year-on-year, primarily due to ongoing equipment orders related to COVID-19 and a steady recovery in routine testing business[16] - The company is focusing on expanding its market presence and enhancing its product development capabilities to drive future growth[38] - The company has not provided specific user data or performance guidance for future quarters in the available documents[65][66] - There is no mention of new product development, market expansion, or mergers and acquisitions in the provided content[65][66] Miscellaneous - The company did not conduct any repurchase transactions among the top 10 shareholders during the reporting period[16] - The company has no significant non-operating fund occupation by controlling shareholders or related parties during the reporting period[31] - The report for the first quarter of 2021 was not audited, indicating that the figures may be subject to change[66] - The first quarter report was released on April 28, 2021, by the legal representative Zhou Qinqin[67]